In conclusion, this study supports the view that CAR-T-CD123 immunotherapy in AML patients may be undermined by the cytokines induced by this therapy and its outcome could be improved by concomitant addition of JAK/STAT or BCL2 inhibitors [153]. The gene discussed is BCL2; the disease is acute myeloid leukemia.